Background: As the global population ages, the prevalence of associated conditions, including neurodegeneration and dementia, will increase. Thus, reducing risk factors is crucial to prevention. Sleep contributes to brain homeostasis and repair, which, if impaired, could lead to neurodegeneration.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
March 2025
Background And Objectives: Low sun and ultraviolet radiation (UVR) exposures have been associated with increased risk of developing pediatric-onset multiple sclerosis (MS); however, their effect on disease course has not been well characterized. We primarily investigated whether there was an association between time spent in the sun in early childhood and risk of relapse in pediatric MS. We secondarily investigated the effect of sun exposure during more recent periods on risk of relapse.
View Article and Find Full Text PDFBackground And Aims: Population aging is associated with the rising incidence of chronic illness. This presents a significant challenge to healthcare systems, particularly in developing countries, as untreated chronic conditions can lead to years of disability and loss of independence straining health budgets and resources. Promoting healthy aging can be one avenue for mitigating these challenges.
View Article and Find Full Text PDFBackground: A brain healthy lifestyle, consisting of good cardiometabolic health and being cognitively and socially active in midlife, is associated with a lower risk of cognitive decline years later. However, it is unclear whether lifestyle changes over time also affect the risk for mild cognitive impairment (MCI)/dementia, and rate of cognitive decline.
Objectives: To investigate if lifestyle changes over time are associated with incident MCI/dementia risk and rate of cognitive decline.
Background: Fatigue is common in multiple sclerosis (MS); it significantly impairs quality of life, and treatment options are limited. A randomized controlled trial of Elevida, a self-guided, online German fatigue intervention, showed significant benefit. We tested an English version of Elevida with people with MS in Australia.
View Article and Find Full Text PDF